MN-202 Emerging Drug Insight

“MN-202 Market Size, Forecast, and Emerging Insight – 2032” report provides comprehensive insights about MN-202 for Major Depressive Disorder (MDD) in the seven major markets. A detailed picture of the MN-202 for MDD in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019 –2032 is provided in this report along with a detailed description of the MN-202 for MDD. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the MN-202 market forecast analysis for MDD in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in MDD.

Drug Summary

MN-202 (Seltorexant) is a selective orexin-2 receptor antagonist under co-development by Janssen Pharmaceutica NV and Minerva as adjunctive therapy for MDD and for the treatment of insomnia disorder. The orexin system in the brain is involved in the control of several key functions, including metabolism, stress response, and wakefulness. This system promotes arousal (wakefulness) and is hypothesized to play a role in excessive arousal, which occurs in subsets of patients with mood disorders and has clinical utility in treating such patients.

Seltorexant is the most advanced specific ORX2 molecule in clinical development, with antagonistic activity when binding to its receptor. Seltorexant is currently being developed for two indications, insomnia without associated psychiatric disorders and MDD in patients who have an inadequate response to SSRIs and SNRIs. Previous clinical trials have indicated that seltorexant might be useful in both indications.

Scope of the Report

The report provides insights into:

•  A comprehensive product overview including the MN-202 description, mechanism of action, dosage and administration, research and development activities in MDD.
•  Elaborated details on MN-202 regulatory milestones and other development activities have been provided in this report.
•  The report also highlights the MN-202 research and development activities in MDD across the United States, Europe and Japan.
•  The report also covers the patents information with expiry timeline around MN-202.
•  The report contains forecasted sales of MN-202 for MDD till 2032.
•  Comprehensive coverage of the late-stage emerging therapies for MDD.
•  The report also features the SWOT analysis with analyst views for MN-202 in MDD.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

MN-202 Analytical Perspective by DelveInsight

• In-depth MN-202 Market Assessment

This report provides a detailed market assessment of MN-202 for MDD in the seven major markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

• MN-202 Clinical Assessment

The report provides the clinical trials information of MN-202 for MDD covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights 

•  In the coming years, the market scenario for MDD is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.  
•  The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence MN-202 dominance.
•  Other emerging products for MDD are expected to give tough market competition to MN-202 and launch of late-stage emerging therapies in the near future will significantly impact the market.
•  A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of MN-202 in MDD.
•  Our in-depth analysis of the forecasted sales data of MN-202 from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the MN-202 in MDD.

Key Questions

•  What is the product type, route of administration and mechanism of action of MN-202?
•  What is the clinical trial status of the study related to MN-202 in MDD and study completion date?
•  What are the key collaborations, mergers and acquisitions, licensing and other activities related to the MN-202 development?
•  What are the key designations that have been granted to MN-202 for MDD?
•  What is the forecasted market scenario of MN-202 for MDD?
•  What are the forecasted sales of MN-202 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan? 
•  What are the other emerging products available and how are these giving competition to MN-202 for MDD?
•  Which are the late-stage emerging therapies under development for the treatment of MDD?